Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6852892 | 1.00 | L3MBTL1 (0.38) | L3MBTL1SMN1; SMN2CA12CA1CA9 | |
| SCHEMBL10997742 | 0.92 | HCAR2 (0.39) | L3MBTL1SMN1; SMN2CA12CA1CA9 | |
| SCHEMBL10859835 | 0.92 | HCAR2 (0.39) | L3MBTL1SMN1; SMN2CA12CA1CA9 | |
| SCHEMBL10859830 | 0.92 | HCAR2 (0.39) | L3MBTL1SMN1; SMN2CA12CA1CA9 | |
| SCHEMBL9418931 | 0.90 | KDM4E (0.37) | L3MBTL1SMN1; SMN2CA12CA1CA9 | |
| SCHEMBL22129952 | 0.88 | SMN1; SMN2 (0.36) | L3MBTL1SMN1; SMN2CA12CA1CA9 | |
| SCHEMBL598007 | 0.83 | L3MBTL1 (0.35) | L3MBTL1SMN1; SMN2CA12CA1CA9 | |
| SCHEMBL1934761 | 0.78 | KEAP1 (0.33) | — | |
| SCHEMBL4018378 | 0.78 | L3MBTL1 (0.41) | L3MBTL1SMN1; SMN2CA12CA1CA9 | |
| SCHEMBL4058405 | 0.78 | KEAP1 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119768395-A | Processes and intermediates for the preparation of viloxazine and other 2-substituted morpholine derivatives | 库里亚西班牙公司 | 2025-04-04 | — | — | CN | disclosed |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| CN-101230008-A | Substituted heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | SANOFI SYNTHELABO (FR) | 2008-07-30 | — | — | CN | disclosed |
| CN-1950089-A | Morpholine compounds | PFIZER LTD (US) | 2007-04-18 | — | — | CN | disclosed |
| CN-1295221-C | Substituted heterocyclic compounds | SANOFI AVENTIS (FR) | 2007-01-17 | — | — | CN | disclosed |
| CN-1293063-C | Substituted heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | SANOFI SYNTHELABO (FR) | 2007-01-03 | — | — | CN | disclosed |
| CN-1889940-A | Treatment of personality changes due to hot flashes, impulse control disorders and systemic medical conditions | LILLY CO ELI (US) | 2007-01-03 | — | — | CN | disclosed |
| CN-1821241-A | Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing same | SANOFI SA (FR) | 2006-08-23 | — | — | CN | disclosed |
| EP-1660064-A2 | TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| CN-1636983-A | Substituted heterocyclic compounds | SANOFI AVENTIS (FR) | 2005-07-13 | — | — | CN | disclosed |
| WO-2005020975-A2 | TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| CN-1179954-C | Substituted heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | ��ŵ�Ѻϳ�ʵ���� | 2004-12-15 | — | — | CN | disclosed |
| CN-1502612-A | Substituted heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | ��ŵ�Ѻϳ�ʵ���� | 2004-06-09 | — | — | CN | disclosed |
| CN-1136189-C | Substd heterocyclic compounds preparing method thereof and pharmaceutical composition contg. them | ��ŵ�Ѻϳ�ʵ���� | 2004-01-28 | — | — | CN | disclosed |
| CN-1394855-A | Substituted heterocyclic compounds | SANOFI SYNTHESIZING LAB (FR) | 2003-02-05 | — | — | CN | disclosed |
| CN-1321639-A | Substituted heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | SANOFI SYNTHESIZING LAB (FR) | 2001-11-14 | — | — | CN | disclosed |
| CN-1321634-A | Substd heterocyclic compounds preparing method thereof and pharmaceutical composition contg. them | SANOFI SYNTHESIZING LAB (FR) | 2001-11-14 | — | — | CN | disclosed |
| CN-1172483-A | Substituted heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1998-02-04 | — | — | CN | disclosed |
| CN-1057648-A | Therapeutical agent | BOOTS CO PLC (GB) | 1992-01-08 | — | — | CN | disclosed |
| US-4698430-A | ANTIDEPRESSANT | A. H. ROBINS COMPANY, INC. (US) | 1987-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | OPRL1, UGT1A1, HTR3B | L3MBTL1 3961/4885SMN1; SMN2 5/4885CA12 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.